banner

Recombinant polyclonal antibodies (rpAb) are a composition consisting of antibodies that bind to different sites on the same antigen  Publications about recombinant polyclonal antibodies
Sympress is used for the manufacture of recombinant polyclonal antibodies Symplex is used for the discovery of recombinant antibodies

Symphogen is developing recombinant polyclonal antibodies (rpAb), a new class of antibody therapeutics for the treatment or prophylaxis of serious human diseases.
 
The development of rpAb presents a significant opportunity to select for both the diversity and specificity of the antibody mixture, thereby capturing the optimal characteristics of the natural human immune response. Their development also presents a number of unique challenges, including how to develop effective methods for discovering and producing rpAb.
 
Symphogen has developed two key technologies to overcome these challenges: Symplex™ is the antibody discovery platform, and Sympress™ is the rpAb manufacturing platform.
Technology